^
    2d
    S101MRD: To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT (clinicaltrials.gov)
    P1, N=18, Recruiting, Peking University People's Hospital
    New P1 trial • Minimal residual disease
    9d
    PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P2, N=100, Recruiting, PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PA3-17
    20d
    Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New P2 trial
    |
    S101
    2ms
    Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Baylor College of Medicine
    New P1 trial
    |
    cyclophosphamide
    2ms
    Immune reconstitution after CD7 CAR-T cell therapy for refractory/relapsed acute T-lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T-ALL/LBL). (PubMed, Br J Haematol)
    We compared infection rates and immune cell subsets in 60 R/R T-ALL/LBL patients receiving naturally selected CD7 CAR-T (NS7CAR-T) with 60 R/R B-ALL patients undergoing CD19 CAR-T...This study indicates that while CD7 CAR-T therapy significantly reduces CD7(+) T cells, it does not lead to increased short-term infection rates. The notable expansion of non-CAR-T-derived CD7(-) T and NK cells helps preserve immune function, highlighting distinct therapeutic mechanisms between CD7 CAR-T and CD19 CAR-T due to their different lineage restrictions.
    Journal
    |
    CD7 (CD7 Molecule)
    |
    S101
    2ms
    CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1 trial
    3ms
    WU-CART-007 1001: A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL (clinicaltrials.gov)
    P1, N=28, Completed, Wugen, Inc. | Phase classification: P1/2 --> P1
    Phase classification
    |
    soficabtagene geleucel (WU CART 007)
    3ms
    PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    New P2 trial
    |
    PA3-17
    3ms
    SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    cytarabine • cyclophosphamide • fludarabine IV
    4ms
    S101P: To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL (clinicaltrials.gov)
    P1, N=18, Recruiting, Peking University People's Hospital
    New P1 trial
    4ms
    A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DM (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Nanjing Bioheng Biotech Co., Ltd.
    New P1 trial
    |
    fludarabine IV • CTD-402
    4ms
    Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy (clinicaltrials.gov)
    P=N/A, N=5, Active, not recruiting, Xuzhou Medical University
    New trial • IO biomarker
    |
    cyclophosphamide • fludarabine IV